Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could help men regrow hair

NCT ID NCT06724614

Disease control Sponsor: Veradermics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months. The goal is to see if the drug safely increases hair count and improves perceived hair growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 480 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is male aged 18-65 years old; * Subject has a clinical diagnosis of mild to moderate AGA; * Subject is in good general health and has normal renal and hepatic function; * Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study; * Subject is willing and able to administer the test article as directed read, understand, and complete required questionnaires in English; * Subject is willing and able to swallow study drug whole; * Subject agrees to have a micro dot tattoo placed on their scalp; * Subject agrees to have this area photographed at study visits as indicated in the protocol. Exclusion Criteria: * Subject has uncontrolled blood pressure or orthostatic hypotension; * Subject has symptoms or history of certain heart or thyroid conditions; * Subject has a history of or active hair loss due to conditions/diseases other than AGA; * Subject has a current or recent history of dietary or weight changes, including use of GLP-1 agonists; * Subject has been diagnosed with COVID-19 within 16 weeks of screening; * Subject has had previous radiation of the scalp; * Use of any of the following treatments within the indicated washout period before screening: * Subject has used hormone replacement therapy or hormonal modulators within 6 months prior to screening * Subject has used oral treatments for hair growth or that can affect hair growth, including systemic retinoids, within 6 months of screening * Subject has used systemic calcium channel blockers or beta blockers within 12 weeks prior to screening * Subject has used systemic cimetidine, ketoconazole, diazoxide, or corticosteroids (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening * Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, injections, platelet rich plasma within 6 months prior to screening * Subject has used any topical scalp treatments for hair growth within 12 weeks prior to screening * Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study; * Subject has any other condition that, in the investigator's opinion, interfere with the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGA Androgenetic alopecia Male pattern baldness

Contacts and locations

Locations

  • Site 01

    Spokane, Washington, 99202, United States

  • Site 02

    Fremont, California, 94538, United States

  • Site 03

    Tampa, Florida, 33613, United States

  • Site 04

    Nashville, Tennessee, 37215, United States

  • Site 05

    Castle Rock, Colorado, 80109, United States

  • Site 06

    New Brighton, Minnesota, 55112, United States

  • Site 07

    Fountain Valley, California, 92728, United States

  • Site 08

    Broomall, Pennsylvania, 19073, United States

  • Site 09

    Knoxville, Tennessee, 37909, United States

  • Site 10

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Site 11

    Columbus, Ohio, 43215, United States

  • Site 12

    Metairie, Louisiana, 70006, United States

  • Site 13

    Covington, Louisiana, 70433, United States

  • Site 14

    Houston, Texas, 77056, United States

  • Site 15

    Indianapolis, Indiana, 46250, United States

  • Site 16

    Murfreesboro, Tennessee, 37130, United States

  • Site 17

    Aventura, Florida, 33180, United States

  • Site 18

    Hackensack, New Jersey, 07601, United States

  • Site 19

    West Jordan, Utah, 84095, United States

  • Site 20

    Greensville, South Carolina, 29615, United States

  • Site 21

    Vista, California, 92083, United States

  • Site 22

    Brighton, Massachusetts, 02135, United States

  • Site 23

    Rolling Meadows, Illinois, 60008, United States

  • Site 24

    Englewood, Colorado, 80111, United States

  • Site 25

    Brandon, Florida, 33511, United States

  • Site 26

    Clarkston, Michigan, 48346, United States

  • Site 27

    West Lafayette, Indiana, 47906, United States

  • Site 28

    Phoenix, Arizona, 85018, United States

  • Site 29

    Lynchburg, Virginia, 24501, United States

  • Site 30

    Fort Smith, Arkansas, 72916, United States

  • Site 31

    Boise, Idaho, 83704, United States

  • Site 32

    New Albany, Indiana, 47150, United States

  • Site 33

    Seattle, Washington, 98168, United States

  • Site 34

    Sherman Oaks, California, 91403, United States

  • Site 35

    Rogers, Arkansas, 72758, United States

  • Site 36

    Birmingham, Alabama, 35203, United States

  • Site 37

    Kew Gardens, New York, 11415, United States

  • Site 38

    New York, New York, 10075, United States

  • Site 39

    Boardman, Ohio, 44512, United States

  • Site 40

    Bellaire, Texas, 77401, United States

  • Site 41

    Baton Rouge, Louisiana, 70809, United States

  • Site 42

    Hollywood, Florida, 33021, United States

  • Site 43

    Atlanta, Georgia, 30329, United States

  • Site 44

    Dallas, Texas, 75231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.